CORRECTION Open Access

Correction to: Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial



Keivan Ranjbar^{1,2}, Mohsen Moghadami^{3*}, Alireza Mirahmadizadeh^{3,4}, Mohammad Javad Fallahi^{1,5}, Vahid Khaloo⁶, Reza Shahriarirad^{1,2}, Amirhossein Erfani^{1,2}, Zohre Khodamoradi^{5,7} and Mohammad Hasan Gholampoor Saadi²

Correction to: BMC Infect Dis 21, 337 (2021) https://doi.org/10.1186/s12879-021-06045-3

Following publication of the original article [1], an error was identified in the Abstract section.

The incorrect sentence is: The patients were randomly allocated into two groups to receive either methylprednisolone (2 mg/kg/day; intervention group) or dexamethasone (6 mg/kg/day; control group).

The correct sentence is: The patients were randomly allocated into two groups to receive either methylprednisolone (2 mg/kg/day; intervention group) or dexamethasone (6 mg/day; control group).

The original article has been corrected.

Author details

¹Thoracic and Vascular Surgery Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. ²Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran. ³Health Policy research center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran. ⁴Non-communicable Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. ⁵Department of Internal Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. ⁶Ali Asghar hospital, Shiraz University of Medical Sciences, Shiraz, Iran. ⁷Shiraz Geriatric Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. ⁷Shiraz Geriatric Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

Published online: 11 May 2021

Reference

 Ranjbar K, et al. Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial. BMC Infect Dis. 2021;21:337. https://doi.org/10.1186/s12879-021-06045-3.

The original article can be found online at https://doi.org/10.1186/s12879-021-06045-3.

Full list of author information is available at the end of the article



© The Author(s). 2021 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

^{*} Correspondence: moghadami@sums.ac.ir

³Health Policy research center, Institute of Health, Shiraz University of Medical Sciences. Shiraz, Iran